The frequency and characteristics of myocardial infarction (MI) subtypes per the Third Universal Definition of MI (TUDMI) classification system using high-sensitivity (hs) cardiac troponin assays with sexspecific cutoffs is not well known. We sought to describe the diagnostic characteristics of type 1 (T1MI) and type 2 (T2MI) MI using an hs-cardiac troponin I (hs-cTnI) assay with sex-specific cutoffs.
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Cardiac troponin has become the preferred biomarker for the diagnosis of myocardial infarction (MI) 5 (1, 2 ). Using contemporary cardiac troponin assays, there is a wide variability in the frequency of type 1 MI (T1MI) (MI related to plaque rupture) and T2MI (MI related to supply/demand imbalance in the absence of plaque rupture). T1MI can range from 33% to 98% of all MIs, with T2MI ranging from 2% to 71% of all MIs (3 ) . This variability depends on the study design, adjudication methodology, and inherent characteristics of the used cardiac troponin assay. Using a contemporary cardiac troponin I (cTnI) assay combined with liberal diagnostic criteria for T2MI, our group previously reported a T2MI frequency of 74% [excluding ST segment elevation MIs (STEMIs)], whereas in another study using a different contemporary cTnI assay combined with strict diagnostic criteria, the T2MI frequency has been reported at 26% (4, 5 ) .
In the US, high-sensitivity (hs)-cTnI and hs-cTnT assays have not been yet cleared by the US Food and Drug Administration for clinical use. It has been anticipated that the frequency of MI might increase once hscardiac troponin assays are cleared (3, 6 ) . Despite the use of hs-cardiac troponin assays in many parts of the world, the frequency and characteristics of MI subtypes according to the Universal Definition of MI classification system using hs-cardiac troponin assays with sexspecific cutoffs is not well known. In anticipation of the clearance of hs-cardiac troponin assays in the US, we conducted a retrospective pilot study with the objective of describing the frequency, characteristics, and mortality of T1MI, T2MI, and non-MI using an hscTnI assay with sex-specific 99th percentile cutoffs in a US population.
Materials and Methods
Following institutional review board approval, patients in whom serial cTnI measurements were obtained on clinical indication at Hennepin County Medical Center (Minneapolis, MN) between November 11 and December 15 2013 were studied. This was an all-comers study involving all patients presenting to the emergency department in whom providers used cTnI to rule in and rule out MI. All patient records were retrospectively reviewed to collect clinical and demographic data. Patients younger than 18 years of age were excluded.
Fresh EDTA plasma samples were simultaneously measured with both the contemporary cTnI and hs-cTnI assays on the Abbott ARCHITECT i1000 SR or i2000 SR analyzers. The contemporary cTnI assay was used by providers for clinical decision-making at the time of the study. The investigational hs-cTnI assay was simultaneously measured. The contemporary cTnI assay had a non-sex-specific 99th percentile URL of 0.030 g/L that was derived in the authors' laboratory. Total betweenday imprecisions (n ϭ 33 days) were 16.3% at 0.035 g/L and 6.1% at 0.15 g/L. The sex-specific 99th percentile cutoffs for the hs-cTnI assay were 16 ng/L for females and 34 ng/L for males (7 ) . Total between-day imprecision (n ϭ 29 days) was 5.3% at 15 ng/L.
EVENT ADJUDICATION
The Third Universal Definition of MI consensus recommendations were used to define acute MI (2 ). T1MI was defined as a spontaneous MI related to atherosclerotic plaque rupture, ulceration, fissuring, erosion, or dissection with resulting intraluminal thrombus. T2MI was defined as an MI secondary to a supply/demand imbalance in the absence of plaque rupture. Our group has recently reviewed the literature on T2MI and developed a set of recommendations for T2MI that were used to guide the adjudication process in this study (3 ) . T2MI was diagnosed when there was evidence of myocardial necrosis in a clinical setting consistent with an acute supply/demand imbalance, without plaque rupture, in which there was a rise and/or fall of cardiac troponin with at least 1 value above the 99th percentile URL, plus at least 1 other criterion of MI according to the Universal Definition of MI.
To guide the diagnosis of MI using the hs-cTnI assay, an algorithm to guide adjudication was developed on the basis of biological variability data using the Abbott Architect hs-cTnI assay from our laboratory [reference change value (RCV) increase, 69.3%; RCV decrease, 40.9%] (8 ). The algorithm followed the template from the study group on biomarkers in cardiology of the ESC Working Group on Acute Cardiac Care (9 ) . If the initial hs-cTnI value was below the sex-specific 99th percentile cutoffs (URL), then a rise of Ͼ69% and/or fall of Ͼ41% in serial sampling were used to suggest a significant rise and/or fall; whereas if the initial hs-cTnI value was increased then a change of at least Ͼ20% was used. MIs were not adjudicated on the basis of falling or rising cTnI values that were within the reference interval (i.e., below the 99th percentile). Patients with an increased hs-cTnI, regardless of having MI or not, were adjudicated into categories according to the Third Universal Definition of MI using sex-specific 99th percentile cutoffs: (a) primary myocardial ischemia, (b) injury related to supply/demand imbalance, (c) injury not related to myocardial ischemia, (d) multifactorial or indeterminate, and (e) unknown (2 ) . The adjudication process also included reporting the "altered" variable(s) within the supply/demand balance, and if no clear variable was altered, then the diagnosis of T2MI was not supported. All cases with either an hs-cTnI above the sex-specific 99th percentile cutoffs or contemporary cTnI above the 99th percentile (sex-specific 99th percentile cutoffs are not valid) were retrospectively examined and underwent MI subtype adjudication after a careful review of available data, including electrocardiogram, echocardiography, angiography, hs-cTnI values, and clinical presentation. Adjudication was performed by one cardiology fellow and verified by an emergency medicine physician in cases of diagnostic uncertainty.
Mortality and length of stay during the index inpatient admission, as well as postdischarge mortality at 150 days, were assessed.
STATISTICAL ANALYSIS
We used 2 tests to compare categorical measures. A Kruskal-Wallis test was used to compare median data. ANOVA was used for continuous numerical data, and Student t-test for comparisons between groups. Kaplan-Meier survival curves were constructed and differences between survival curves were compared using the log-rank statistic. Statistical significance was accepted at the 0.05 level. Analyses were performed with MedCalc v13.
Results
A total of 310 patients with serial hs-cTnI measurements were enrolled in the study. Baseline clinical characteristics of events using the hs-cTnI assay are shown in Table 1 . One hundred twenty-seven (41%) patients had at least 1 hs-cTnI above the sex-specific 99th percentile cutoffs, whereas 183 (59%) had an hs-cTnI within the reference interval. Myocardial necrosis etiologies are shown in Table 2 . The most common Prior coronary artery bypass graft, n (%) 0 (0) 1 (5) 9 (9) 8 (4) 0.62
History of congestive heart failure, n (%) 2 (20) 4 (18) 24 (25) 26 (14) 0.43
History of atrial fibrillation, n (%) 1 (10) 1 (5) 8 (8) 8 (4) 0.81
Cerebrovascular disease, n (%) 1 (10) 2 (9) 12 (13) 18 (10) Table 2 . Myocardial necrosis etiologies using hs-cTnI sex-specific cutoffs.
Myocardial necrosis etiologies using hs-cTnI sex-specific cutoffs Males, >34 ng/L Females, >16 ng/L All with increased hs-cTnI values using sex cutoffs P value Total (n = 310) n = 66 n = 61 n = 127
Injury related to primary myocardial ischemia, n (%) causes of hs-cTnI increases were multifactorial or indeterminate injury (43%). According to sex, females had more myocardial injury related to supply/demand ischemia than males (39% vs 18%, P ϭ 0.01), whereas males had more multifactorial or indeterminate injury (52% vs 33%, P ϭ 0.05). There were 32 (10%) acute MIs, among which 10 (3%) were T1MI and 22 (7%) were T2MI. T2MI represented 69% (22 out of 32) of all acute MIs, whereas T1MI represented 31% (10 out of 32). Ninety-five patients (31%) had an increased hs-cTnI above the sexspecific 99th percentile cutoffs but did not meet criteria for acute MI and were categorized as non-MI hs-cTnI increases. The remaining 183 (59%) patients had hscTnI values within the reference interval and were categorized as no MI with normal hs-cTnI. In contrast to when hs-cTnI values were used for adjudication, based on the contemporary cTnI assay, a greater number of patients (n ϭ 43) were adjudicated to have an acute MI, among which 14 (4.5% of all patients, 32.5% of all acute MIs) had a T1MI, and 29 (9.4% of all patients, 67.4% of all acute MIs) had a T2MI. Fig. 1 exemplifies serial cTnI patterns of 2 patients that were adjudicated as no MI using the hs-cTnI assay compared to the contemporary cTnI assay.
Patients with T2MI had a higher mean heart rate than T1MI (116 vs 88 beats per minute, P ϭ 0.007). Both T1MI and T2MI had similar rates of history of renal insufficiency (20% vs 23%, P ϭ 0.77) and congestive heart failure (20% vs 18%, P ϭ 0.71). Patients with T2MI and non-MI with hs-cTnI increases tended to have more end-stage renal disease on hemodialysis, in contrast to patients with T1MI, as shown in Table 1 .
The most common triggers for T2MI were tachyarrhythmias (8/22, 36%), hypotension/shock (8/22, 36%), and hypertension (6/22, 27%). T2MI could be deemed to be triggered by either 1 isolated altered variable within the supply/demand balance or more than 1 variable. Nine T2MI had a combination of altered variables (i.e., respiratory failure and hypertension), whereas the remaining 13 were deemed to have T2MI triggered by an isolated variable.
Patients with T1MI, including 1 STEMI patient, had significantly higher concentrations of cTnI compared to T2MI for both initial and maximum values using both hs-and contemporary cTnI assays (P Ͻ 0.001). With the use of the hs-cTnI assay, patients with T1MI had a mean initial value of 913 ng/L compared to 259 ng/L in patients with T2MI (P ϭ 0.2). Similarly, patients having T1MI had a maximum mean value of 7767 ng/L compared to 615 ng/L in patients with T2MI (P ϭ 0.02). Compared to T2MI patients, patients adjudicated as "no MI with increased hs-cTnI assay concentrations" had maximum hs-cTnI concentrations that were significantly different (211 vs 615 ng/L, P ϭ 0.04). hs-Cardiac troponin values among subgroups are shown in Table 3 .
Men having a T1MI had initial and maximum mean hs-cTnI concentrations of 1706 and 11 133 ng/L respectively, in contrast with T2MI concentrations of 55 ng/L and 452 ng/L, respectively. Women having a T1MI had mean initial and maximum hs-cTnI concentrations of Fig. 1 . Representative serial cTnI concentrations in 2 patients measured by contemporary and hs-cTnI assays. Table 3 . Cardiac troponin concentrations using hs-cTnI assay and associated biomarkers. 120 ng/L and 4401 ng/L, respectively, in contrast with T2MI concentrations of 400 ng/L and 727 ng/L, respectively (Table 4) . Although not significant, the mean initial value in women with T2MI was higher than the initial value in women with T1MI (400 vs 120 ng/L, P ϭ 0.6), but maximum values were lower in women with T2MI than in those with T1MI (727 vs 4401 ng/L, P ϭ 0.2). The majority of postdischarge deaths occurred in patients with no MI and increased hs-cTnI [12 deaths (13%) at 150 days], as shown in Fig. 2 . Causes of death included the following comorbidities: sepsis, intracerebral hemorrhage, ischemic kidney disease, hemorrhagic shock, acute renal failure, congestive heart failure, and cardiac arrest. Patients with T2MI had a mean length of stay of 9.5 days (range, 3.4 -15.6 days), with a limited number of events. During the index admission there was only 1 death in the T2MI group, in contrast to no deaths among T1MI group. Patients having no MI and increased hs-cardiac troponin had 4 deaths. During followup, postdischarge mortality remained the same, with no further events among patients with T1MI and only 1 death in the T2MI cohort.
Discussion
Several findings are unique to this study using an hs-cTnI assay with sex-specific 99th-percentile cutoffs. First, it must be noted that the objective of our study was to assess the frequency and characteristics of T1MI, T2MI, and non-MI obtained with an hs-cTnI assay in a US center in which a contemporary cTnI was in use for clinical decision-making at the time of the study. Despite the general expectation by clinicians that the introduction of hs-cTnI assays would lead to an increased detection of events, we noted a similar rate of T1MI and T2MI using the hs-cTnI assay. The T1MI and T2MI overall frequency rates among the whole study population were 3% and 7%, respectively, using the hs-cTnI assay with sexspecific 99 th -percentile cutoffs, in comparison to 4.5% and 9.4% using the contemporary cTnI assay. This observation is limited by the size of our study and number of events. Further validation will be required to confirm if indeed the rate of T1MI and T2MI events does not increase with the introduction of hs-cardiac troponin assays. Our research group has just completed enrolling patients into a large study (ClinicalTrials.gov identifier: NCT02060760) in which we expect to encounter a larger number of clinical events and determine if this observation stands.
Second, the lack of an expected increase in T1MI and T2MI events when adjudicating with hs-cTnI vs contemporary cTnI may be related to the combination of an analytically improved hs-cTnI assay in addition to a careful adjudication process. As shown in Fig. 1 , analytical variation in the contemporary cTnI assay shows "analytical noise" for concentration values near the 99th percentile, leading to a falsely higher number of events diagnosed and/or adjudicated as having an MI, because the minor cardiac troponin value increases above the 99th percentile URL may be encountered in combination with at least 1 other criterion for the diagnosis of acute MI. In contrast, with the use of the hs-cTnI assay with higher precision (less analytical noise), only cTnI increases indicative of myocardial injury should be observed (8 ) .
Third, we report distinct concentration differences between T1MI and T2MI using an hs-cTnI assay with sex-specific 99th percentile cutoffs. Patients with T2MI had significantly lower initial and maximum mean concentrations (259 vs 913 ng/L and 1186 vs 7767 ng/L, both P Ͻ 0. 0001) in contrast to T1MI. When we stratified MI into subtypes and categorized patients by sex, we confirmed, as expected, that men had higher initial hscTnI concentrations and maximum concentrations that were higher than those for women in T1MI (10 ) . Surprisingly, hs-cTnI concentrations in women with T2MI trended higher than those in men. Also unexpected was that the mean initial value in women with T2MI was not different than the initial value in women with T1MI. As anticipated, the mean maximum hs-cTnI values were significantly lower in women with T2MI than in those with T1MI (614 vs 7767 ng/L, P ϭ 0.02). Again, these comparisons are limited by the small sample size. Larger studies observing sex differences in MI subtypes with hs-cTnI will be required to further delineate and clarify these findings. Fourth, we noted that the most common triggers of T2MI were tachyarrhythmias and hypotension. Using a contemporary cTnI assay combined with strict diagnostic criteria for T2MI, Saaby et al. reported that anemia, tachyarrhythmias, and respiratory failure were the most common mechanisms associated with T2MI (5 ). However it remains controversial if there should or should not be a degree and/or threshold of increased demand or decreased supply that are necessary to qualify as a T2MI (3, 5, 11 ) . Saaby et al. used "strict" criteria, whereas we used an individualized, more liberal approach in which all factors are subjectively assessed and adjudicated trigger(s) are coded in the current study. Further guidance is required in this area, because the frequency of T2MI reported varies depending on the use of strict vs "liberal" criteria (3 ). As supply/demand ischemia is a multifactorial process dependent on multiple anatomic (e.g., presence of fixed stable coronary stenosis or left ventricular hypertrophy) and physiologic (e.g., oxygenation, hemoglobin, heart rate, arterial blood pressure) variables, it is impossible to use any single strict cutoff for any single variable.
We note several limitations with our current observations. First, limited numbers of both acute MIs and deaths were encountered related to sample size, and a robust conclusion on outcomes cannot be offered because there was only 1 death in both T1MIs and T2MIs during the index hospitalization and follow-up. Noncardiac comorbidities with an increased cTnI included sepsis, intracerebral hemorrhage, ischemic kidney disease, hemorrhagic shock, and acute renal failure; all of these factors are known to be associated with an increased risk of death. Second, no conclusive statements can be made about the observed sex differences in hs-cTnI concentrations owing to the limited number of events. Third, future, larger studies will be needed to address the use of age-defined 99th percentile cutoffs and sex-defined deltas for diagnostic accuracy studies. Fourth, only 1 clinician reviewed cases for adjudication. However, verification by a second clinician was available in diagnostically challenging cases. A larger study ongoing in our laboratory (ClinicalTrials.gov identifier: NCT02060760) has at least 2 adjudicators reviewing each case with an additional clinician adjudicator in case of discrepancy. Finally, our study was a descriptive study observing T1MI and T2MI regardless of the presence of STEMI (n ϭ 1), rather than a diagnostic accuracy study.
In conclusion, in this pilot study comparing T1MI and T2MI with use of both a contemporary cTnI and hs-cTnI, we found that there were fewer MI diagnoses when using hs-cTnI values, contrary to the commonly accepted idea that hs-cTnI results will lead to excessive false-positive diagnoses. Our study emphasizes the impact of improved precision with hs-cTnI over cTnI on the diagnosis of T1MI and T2MI.
